Evaluation of IL-2 and IL-7 Expression in Patients With Prostate Cancer

Background: Prostate cancer is a biologically heterogeneous disease which has become the fifth leading cause of cancer-related deaths in men worldwide. Interleukins (ILs) display required inflammation moderator. IL-2 and IL-7 play significant roles in regulating cancer-immune system interactions. So, the purpose of this investigation was to evaluate the expression level of IL-2 and IL-7 in prostate cancer patients and healthy subjects. Materials and Methods: In this case-control study, expression of IL-2 and IL-7 was examined in peripheral blood of 40 prostate cancer patients and 40 healthy subjects by reverse transcription quantitative real-time polymerase chain reaction. Results: Our findings showed that IL-7 has highly elevated expression in patients with prostate cancer compared to healthy subjects (P=0.0001). In contrast, no significant difference was observed in the expression of the IL-2 between the two study groups (P=0.12). Conclusion: Based on the results, IL-7 may be used as a prospective biomarker or as a molecular target in designing new prostate cancer control strategies. However, the findings of this investigation revealed no association between IL-2 expression and prostate cancer. Nevertheless, more studies should be included to appraise the exact relevance of this gene to prostate cancer.